China Cord Blood (NYSE: CO) reported earnings on Feb. 27. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q3), China Cord Blood met expectations on revenue and met expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share increased significantly.

Gross margin increased, operating margin dropped, and net margin increased.

Revenue details
China Cord Blood logged revenue of $15.1 million. The one analyst polled by S&P Capital IQ expected sales of $15.0 million on the same basis. GAAP reported sales were 9.6% higher than the prior-year quarter's $13.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $0.06. The one earnings estimate compiled by S&P Capital IQ averaged $0.06 per share on the same basis. GAAP EPS of $0.09 for Q3 were 80% higher than the prior-year quarter's $0.05 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 77.1%, 30 basis points better than the prior-year quarter. Operating margin was 33.2%, 530 basis points worse than the prior-year quarter. Net margin was 41.6%, 1,300 basis points better than the prior-year quarter.

Looking ahead

Next year's average estimate for revenue is $59.2 million. The average EPS estimate is $0.23.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 32 members out of 52 rating the stock outperform, and 20 members rating it underperform. Among 15 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), five give China Cord Blood a green thumbs-up, and 10 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on China Cord Blood is buy, with an average price target of $5.75.

Over the decades, small-cap stocks like China Cord Blood have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.